At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 418 enrolled
Drug / intervention
Oliceridine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active-controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy
In Brief
A Phase 3 clinical trial evaluating Oliceridine, Placebo, and 1 other intervention for Acute Pain. Completed, enrolled 418 participants across 7 sites.
Detailed Summary
The primary objective is to evaluate the analgesic efficacy of intravenous (IV) oliceridine administered as needed (PRN) compared with placebo in patients with moderate to severe acute postoperative pain after bunionectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Pain
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMay 2016
First PostedJun 2016
Primary CompletionDec 2016
Study CompletionJan 2017
TodayJul 2026
First PostedJun 28, 2016
Enrollment StartMay 1, 2016
Primary CompletionDec 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.0 years ago
Interventions
Oliceridinedrug
Placebodrug
Morphinedrug